2-甲氧基-6-甲基苯甲酸 | 6161-65-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-6-甲基苯甲酸
• 中文别名: 6-甲基-2-甲氧基苯甲酸；2-甲基-6-甲氧基苯甲酸
• 英文名称: 2-methoxy-6-methyl-benzoic acid
• 英文别名: 6-Methoxy-2-methyl-benzoesaeure；2-Methoxy-6-methyl-benzoesaeure；2-Methyl-6-methoxy-benzoesaeure；2-Methoxy-6-methylbenzoic acid
• CAS: 6161-65-5
• 化学式: C₉H₁₀O₃
• mdl: MFCD00463871
• 分子量: 166.177
• InChiKey: MICCJGFEXKNBLU-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  140 °C(Press: 18 Torr)
• 密度：
  1.168±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methoxy-6-methylbenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methoxy-6-methylbenzoic acid
CAS number: 6161-65-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10O3
Molecular weight: 166.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基-6-甲基苯甲酸 在 哌嗪 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 10.0h， 以52%的产率得到2-羟基-6-甲基苯甲酸
  参考文献：
  名称：

  Regioselective Dealkylation of 2-Alkoxybenzoic Acid and Its Amide Derivatives with Aliphatic Amines

  摘要：

  邻甲氧基苯甲酸与脂肪族胺在非烷基双极性溶剂中发生裂解反应。当使用二甲基乙酰胺中的哌嗪时，这种裂解反应尤其顺利。这种方法适用于邻烷氧基苯甲酸及其酰胺衍生物的各种脱烷反应，具有很高的区域选择性。

  DOI：

  10.1055/s-2000-6244
• 作为产物：
  描述：

  间甲基苯甲醚 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 2-甲氧基-6-甲基苯甲酸
  参考文献：
  名称：

  正丁基锂在某些芳香族底物的金属化过程中的产物分布

  摘要：

  苯甲醚，三氟甲苯，苯乙醚，：下面的化合物用在醚中的正丁基锂和产物异构体用的气相色谱技术辅助确定比金属化米甲酚甲基醚，间苯二酚二甲醚和联苯基。除联苯外，所有底物的数据均符合不同环位置的相对进攻速率的观点，该相对位置的进攻速率受环取代基对环碳氢键“酸度”的感应影响所控制。

  DOI：

  10.1016/0022-328x(68)80043-9

文献信息

• [EN] CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES CARBOCYCLIQUES DU RÉCEPTEUR GLYT1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011023667A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of general formula (I) wherein R1/R2 are independently from each other hydrogen, lower alkyl, -CH2)o-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl; or R1 and R2 are together with the N-atom to which they are attached a ring containing -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-S-(CH2)2-, -(CH2)2-NR-(CH2)2-, -(CH2)2-C(O)-(CH2)2-, -(CH2)2-CF2-(CH2)2-, -CH2-CHR-(CH2)2, -CHR-(CH2)3, CHR-(CH2)2-CHR-, or is the ring 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester and R is hydroxy, halogen, cycloalkyl, or C(O)O-lower alkyl; X is -(CH2)4-, -(CH2)3-, -(CH2)2- or -CH2-; R3 is S-lower alkyl, CF3, OCHF2, lower alkoxy, lower alkyl, phenyl, cycloalkyl or halogen; R4 is CF3, lower alkoxy, lower alkyl, halogen and n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers thereof for the manufacture of a medicament for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及一种通式(I)的化合物的使用，其中R1/R2分别独立地为氢、较低的烷基、-CH2)o-环烷基，其中o为0或1，或者为苄基或杂环烷基；或者R1和R2与它们连接的N原子一起形成一个含有-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)2-O-(CH2)2-、-(CH2)2-S-(CH2)2-、-(CH2)2-NR-(CH2)2-、-(CH2)2-C(O)-(CH2)2-、-(CH2)2-CF2-(CH2)2-、-CH2-CHR-(CH2)2、-CHR-(CH2)3、CHR-(CH2)2-CHR-的环，或者是环2,6-二氮杂螺[3.3]庚烷-2-羧酸叔丁基酯，R为羟基、卤素、环烷基或C(O)O-较低烷基；X为-(CH2)4-、-(CH2)3-、-(CH2)2-或-CH2-；R3为S-较低烷基、CF3、OCHF2、较低烷氧基、较低烷基、苯基、环烷基或卤素；R4为CF3、较低烷氧基、较低烷基、卤素，n为1或2；或者用于制备用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病的药物的药学上可接受的酸盐、外消旋混合物或其相应的对映体和/或光学异构体。
• Synthesis and Structure‐Activity Relationship of Xenocoumacin 1 and Analogues as Inhibitors of Ribosomal Protein Synthesis
  作者：Cornelia Zumbrunn、Daniela Krüsi、Christina Stamm、Patrick Caspers、Daniel Ritz、Georg Rueedi

  DOI：10.1002/cmdc.202000793

  日期：2021.3.3

  Ribosomal protein synthesis is an important target in antibacterial drug discovery. Numerous natural products have served as starting points for the development of antibiotics. We report here the total synthesis of xenocoumacin 1, a natural product that binds to 16S ribosomal RNA at a highly conserved region, as well as analogues thereof. Preliminary structure–activity relationship studies were aimed

  核糖体蛋白合成是抗菌药物发现的重要目标。许多天然产物已成为抗生素开发的起点。我们在此报告异香豆素 1 的全合成，这是一种在高度保守的区域与 16S 核糖体 RNA 结合的天然产物及其类似物。初步的构效关系研究旨在了解和调节真核和原核核糖体之间的选择性。修饰主要在芳香区域被容忍。对革兰氏阴性菌的全细胞活性受到外排和渗透的限制，正如在大肠杆菌的转基因菌株中所证明的那样. 鉴定了对真核生物核糖体具有高选择性的类似物，但不可能获得对细菌蛋白质合成具有选择性的抑制剂。尽管真核和原核核糖体在结合区具有高度同源性，但实现高选择性（尽管不是理想的）是可能的。
• Distal γ‐C(sp ³ )−H Olefination of Ketone Derivatives and Free Carboxylic Acids
  作者：Han Seul Park、Zhoulong Fan、Ru‐Yi Zhu、Jin‐Quan Yu

  DOI：10.1002/anie.202003271

  日期：2020.7.27

  Reported herein is the distal γ‐C(sp3)−H olefination of ketone derivatives and free carboxylic acids. Fine tuning of a previously reported imino‐acid directing group and using the ligand combination of a mono‐N‐protected amino acid (MPAA) and an electron‐deficient 2‐pyridone were critical for the γ‐C(sp3)−H olefination of ketone substrates. In addition, MPAAs enabled the γ‐C(sp3)−H olefination of free carboxylic

  本文报道了酮衍生物和游离羧酸的远端γ-C(sp 3 )-H烯化。微调先前报道的亚氨基酸导向基团并使用单N保护氨基酸（MPAA）和缺电子2-吡啶酮的配体组合对于γ-C(sp 3 )-H烯化至关重要酮底物。此外，MPAA 能够使游离羧酸发生 γ-C(sp 3 )-H 烯化反应，形成多种六元内酯。除了烷基羧酸之外，苄基 C(sp 3 )−H 键也可以通过 2-甲基苯甲酸衍生物一步功能化形成 3,4-二氢异香豆素结构。这些方案的实用性在大规模反应和 γ-C(sp 3 )−H 烯化产物的多样化中得到了证明。
• Substituted Indoles
  申请人：AbbVie Inc.

  公开号：US20170174688A1

  公开（公告）日：2017-06-22

  The invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  该发明提供了以下式（I）的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 和R 6 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由SUV420H1介导和调节的疾病和症状中作为药剂是有用的。还提供了由一个或多个式（I）化合物组成的药物组合物。
• CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS
  申请人：Kolczewski Sabine

  公开号：US20110053904A1

  公开（公告）日：2011-03-03

  The present invention relates to the use of a compound of formula I wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

  本发明涉及使用式I的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，X和n如本文所定义 或其药学上可接受的酸盐，或其相应的对映体和/或光学异构体，用于治疗精神病、疼痛、记忆和学习功能障碍、注意力缺陷、精神分裂症、痴呆症或阿尔茨海默病。

表征谱图